Evidence map›Paper›PMID 40038578›Full record

ArticleBMC immunology2025

Bacille Calmette-Guérin-specific IgG titres among infants born to mothers with active tuberculosis disease in Uganda.

Diana Sitenda, Phillip Ssekamatte, Rose Nakavuma, Andrew Peter Kyazze, Felix Bongomin, Joseph Baruch Baluku, Rose Nabatanzi, Davis Kibirige, Robert J Wilkinson, Annettee Nakimuli and 2 more

Abstract read
In one paragraph

Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Diana SitendaDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda. dianasitenda@gmail.com.
Phillip SsekamatteDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Rose NakavumaTuberculosis and Comorbidities Research Consortium, Kampala, Uganda.
Andrew Peter KyazzeTuberculosis and Comorbidities Research Consortium, Kampala, Uganda.
Felix BongominDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University (GU), Gulu, Uganda.
Joseph Baruch BalukuDivision of Pulmonology, Kiruddu National Referral Hospital, Kampala, Uganda.
Rose NabatanziDepartment of Immunology and Molecular Biology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda.
Davis KibirigeTuberculosis and Comorbidities Research Consortium, Kampala, Uganda.
Robert J WilkinsonFrancis Crick Institute, London, UK.
Annettee NakimuliDepartment of Obstetrics and Gynaecology, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Stephen CoseMedical Research Council, Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine, Entebbe, Uganda.
Irene Andia-BiraroTuberculosis and Comorbidities Research Consortium, Kampala, Uganda.

Funding

Wellcome Trust (CC2112)Wellcome Trust CC2112
6 · The paper itself

Abstract

backgroundInfants born to mothers with active tuberculosis disease (ATB) are at risk of poor clinical outcomes such as low birth weight and perinatal mortality. However, little is known about the influence of maternal ATB exposure on their vaccine responses during infancy. The study explored how maternal ATB affects infants' vaccine responses, hypothesising reduced responses to Bacille Calmette-Guérin (BCG) and other infant vaccines.

methodsThis was a case-control study with a longitudinal component of infants born to mothers with bacteriologically confirmed ATB (cases) and infants born to mothers without ATB (controls) carried out between September 2021 and June 2022. Quantitative BCG, diphtheria, tetanus, and measles-specific IgG ELISA assays were performed on infant plasma harvested from lithium-heparin blood collected on first encounter after birth (0), at 3, 6, and 9 months. We used prism v10.1.2, mixed-effects modelling, and Tukey's multiple comparison testing to determine mean differences (MD) between the cases and controls at all time points.

resultsExposed infant cases had reduced IgG titres to BCG at baseline compared to the controls (p = 0.032), with a mean of 125.8 vs. 141.1 IU/mL, respectively. This difference was, however, not sustained at the other time points. Similarly, we demonstrated trends towards reduced responses to tetanus, diphtheria, and measles vaccines among infant cases at baseline and three months. However, the trend was not sustained at months six and nine. The mean titres for tetanus at baseline and 3 months for cases versus controls are 1.744 vs. 2.917 IU/mL (p < 0.0001) and 1.716 vs. 2.344 IU/mL (p = 0.018), respectively. The mean titres for diphtheria at 3 months for cases versus controls were 0.022 vs. 0.075 IU/mL (p = 0.006), respectively.

conclusionWe have demonstrated that maternal TB disease influences vaccine responses to BCG and other infant vaccines. This has implications for increased risk of childhood TB and other preventable diseases. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Antibodies, BacterialBCG VaccineImmunoglobulin GTuberculosisAdultCase-Control StudiesFemaleHumansInfantInfant, NewbornMalePregnancyUgandaAntibodies, BacterialBCG VaccineImmunoglobulin GActive tuberculosisInfantsMothersVaccine response

Identifiers

PMID40038578
PMCPMC11877890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.